Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SLDB
stocks logo

SLDB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.595
-40.54%
--
--
-0.516
-12.53%
--
--
-0.522
+24.38%
Estimates Revision
The market is revising No Change the revenue expectations for Solid Biosciences Inc. (SLDB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 7.64%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.02%
In Past 3 Month
Stock Price
Go Up
up Image
+7.64%
In Past 3 Month
Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.29 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.29 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.920
sliders
Low
9.00
Averages
14.29
High
20.00
Current: 5.920
sliders
Low
9.00
Averages
14.29
High
20.00
Needham
NULL -> Buy
initiated
$16
2025-12-04
New
Reason
Needham
Price Target
$16
2025-12-04
New
initiated
NULL -> Buy
Reason
Needham initiated coverage of Solid Biosciences (SLDB) with a Buy rating and $16 price target. The firm believes the recent deaths in two non-ambulatory Duchenne muscular dystrophy patients on Sarepta's (SRPT) Elevidys calls into question the drug's benefit/risk profile and may provide an opening for emerging competitors such as Solid's gene therapy SGT-003. SGT-003 is designed to minimize liver toxicity without compromising on efficacy and its early results show robust microdystrophin expression, the analyst tells investors in a research note.
Needham
Gil Blum
Buy
initiated
$16
2025-12-04
New
Reason
Needham
Gil Blum
Price Target
$16
2025-12-04
New
initiated
Buy
Reason
Needham analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target.
JPMorgan
Overweight -> Overweight
downgrade
$13 -> $11
2025-11-05
Reason
JPMorgan
Price Target
$13 -> $11
2025-11-05
downgrade
Overweight -> Overweight
Reason
JPMorgan lowered the firm's price target on Solid Biosciences to $11 from $13 and keeps an Overweight rating on the shares. The firm updated the company's model.
Citi
Buy
downgrade
$16 -> $14
2025-11-05
Reason
Citi
Price Target
$16 -> $14
2025-11-05
downgrade
Buy
Reason
Citi lowered the firm's price target on Solid Biosciences to $14 from $16 and keeps a Buy rating on the shares following data from the Phase 1/2 INSPIRE-DUCHENNE trial. The firm says microdystrophin expression after 90 days dropped.
Barclays
Overweight
downgrade
$10 -> $9
2025-11-04
Reason
Barclays
Price Target
$10 -> $9
2025-11-04
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Solid Biosciences to $9 from $10 and keeps an Overweight rating on the shares. The company's Q3 brought "encouraging" interim data for SGT-003 with a 58% microdystrophin protein level in 10 patients, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
2025-06-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-06-18
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating on Solid Biosciences (SLDB) after Sarepta (SRPT) disclosed a second patient death due to acute liver failure following treatment with Elevidys. The news underscores the favorable safety profile of Solid's SGT-003, the analyst tells investors in a research note. The firm believes SGT-003 has the most favorable safety profile among the leading Duchenne muscular dystrophy gene therapies either in clinic or in the market. Wainwright expects a meaningful share of ambulatory patients to transition from Elevidys to SGT-003.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Solid Biosciences Inc (SLDB.O) is -2.89, compared to its 5-year average forward P/E of -2.79. For a more detailed relative valuation and DCF analysis to assess Solid Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.79
Current PE
-2.89
Overvalued PE
-0.65
Undervalued PE
-4.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.70
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.62
Undervalued EV/EBITDA
-2.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
29.30
Current PS
0.00
Overvalued PS
76.96
Undervalued PS
-18.35
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 767.4% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 767.4% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SLDB News & Events

Events Timeline

(ET)
2025-12-01
08:20:00
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212
select
2025-11-17 (ET)
2025-11-17
08:09:48
Solid Biosciences Forms Licensing Partnership with Andelyn Biosciences
select
2025-11-06 (ET)
2025-11-06
08:11:44
Solid Biosciences Receives Innovation Passport for SGT-003 Under ILAP
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
04:38 AMBenzinga
Solid Biosciences: Analyst Optimistic About Company's Competitive Edge in DMD Gene Therapy

  • Emerging Gene Therapies: Recent patient deaths linked to Sarepta Therapeutics' gene therapy have increased interest in Solid Biosciences' SGT-003, which aims to reduce liver toxicity while maintaining efficacy in treating Duchenne muscular dystrophy (DMD).

  • Analyst Coverage and Ratings: Needham analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and a price target of $16, highlighting the promising early results of SGT-003.

  • Regulatory Outlook: Regulatory updates expected in the first half of 2026 may accelerate the approval process for SGT-003, with Phase I studies anticipated to begin in late 2025.

  • Financial Position: Solid Biosciences reported a cash position of $268 million, which is projected to sustain operations into the first half of 2027, while shares have seen a notable increase.

[object Object]
Preview
4.0
12-04Benzinga
AutoZone Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations

  • Analyst Coverage Initiations: Several top Wall Street analysts have initiated coverage on various companies, providing new ratings and price targets.

  • Solid Biosciences Inc: Needham analyst Gil Blum rated Solid Biosciences with a Buy and set a price target of $16, while shares closed at $5.19.

  • AutoZone, Inc: Baird analyst Justin Kleber rated AutoZone as Outperform with a price target of $4,500, with shares closing at $3,822.92.

  • Other Companies: Analysts also initiated coverage on ASP Isotopes, Paymentus Holdings, and monday.com, with respective ratings and price targets indicating potential growth.

[object Object]
Preview
9.0
12-01Newsfilter
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212, Initiates Clinical Trial
  • FDA Designation: Solid Biosciences' SGT-212 has received FDA's Rare Pediatric Disease and Fast Track designations, marking a significant advancement in the treatment of Friedreich's ataxia, which is expected to accelerate clinical trials and market access.
  • Clinical Trial Initiation: Participant screening for the FALCON Phase 1b clinical trial is underway, utilizing a dual-route administration approach to restore therapeutic frataxin protein levels, addressing neurological, cardiac, and systemic manifestations of the disease.
  • Market Potential: Friedreich's ataxia affects approximately 5,000 patients in the U.S. and 15,000 in Europe, with no effective treatments currently available; successful development of SGT-212 could fill this market gap and meet unmet medical needs.
  • Strategic Implications: The Rare Pediatric Disease designation not only enhances engagement with regulators but may also provide a priority review voucher for future Biologic License Applications, thereby increasing the company's competitiveness in the gene therapy sector.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Solid Biosciences Inc (SLDB) stock price today?

The current price of SLDB is 5.92 USD — it has increased 14.07 % in the last trading day.

arrow icon

What is Solid Biosciences Inc (SLDB)'s business?

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

arrow icon

What is the price predicton of SLDB Stock?

Wall Street analysts forecast SLDB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDB is 14.29 USD with a low forecast of 9.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Solid Biosciences Inc (SLDB)'s revenue for the last quarter?

Solid Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Solid Biosciences Inc (SLDB)'s earnings per share (EPS) for the last quarter?

Solid Biosciences Inc. EPS for the last quarter amounts to -0.48 USD, decreased -39.24 % YoY.

arrow icon

What changes have occurred in the market's expectations for Solid Biosciences Inc (SLDB)'s fundamentals?

The market is revising No Change the revenue expectations for Solid Biosciences Inc. (SLDB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 7.64%.
arrow icon

How many employees does Solid Biosciences Inc (SLDB). have?

Solid Biosciences Inc (SLDB) has 100 emplpoyees as of December 05 2025.

arrow icon

What is Solid Biosciences Inc (SLDB) market cap?

Today SLDB has the market capitalization of 460.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free